A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

This trial is testing whether a combination of two drugs — zibotentan and dapagliflozin — reduces protein in the urine and slows kidney function decline better than dapagliflozin alone in adults with chronic kidney disease (CKD) and high levels of protein leaking into the urine. **You may be eligible if...** - You are 18 or older - You have CKD with a moderately reduced kidney filtration rate (eGFR 20–89) AND significantly elevated urinary protein levels (UACR over 700 mg/g) - Your BMI is 40 or below - You are already on a stable dose of an ACE inhibitor or ARB blood pressure/kidney medication **You may NOT be eligible if...** - You have severe heart failure (NYHA Class III or IV) - You have had a recent hospitalisation for heart-related reasons - You are allergic to dapagliflozin or related drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.